← SINOVAC BIOTECH LTD (SVA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
SINOVAC BIOTECH LTD (SVA)
Pharmaceutical Preparations · market cap $465M · as of 2026-07-07
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
20
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Sinovac Biotech Ltd (SVA) is a China-focused vaccine developer with a market cap of approximately $465M and a share price of ~$6.47. The company operates a broad pipeline of Phase 2 and Phase 3 vaccines spanning varicella, hand-foot-and-mouth disease (HFMD), poliomyelitis, influenza, pneumococcal infections, herpes zoster, tetanus, and COVID-19. The nearest binary event is an estimated Phase 3 readout for lead asset PROVARIX (varicella vaccine) on or around July 15, 2026.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| PROVARIX | Phase 3 | Varicella (Chickenpox) |
| 36-71 months old children-experimental EV71 vaccine. | Phase 3 | Hand, Foot and Mouth Disease |
| investigational 23-valent PPV | Phase 3 | Pneumococcal Infections |
| 400U /0.5ml EV71 vaccine | Phase 3 | Hand, Foot and Mouth Disease |
| Investigational sIPV | Phase 3 | Poliomyelitis |
| three consecutive lots of EV71 vaccine | Phase 3 | Hand, Foot and Mouth Disease |
| Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age | Phase 3 | Poliomyelitis |
| Quadrivalent influenza vaccine | Phase 3 | Seasonal Influenza |
| Single-dose regimen of high dosage investigational sIPV | Phase 2 | Poliomyelitis |
| sIPV-sIPV-bOPV vaccination schedule | Phase 3 | Poliomyelitis |
| Trivalent influenza vaccine (contains B/Victoria strain) | Phase 3 | Seasonal Influenza |
| pandemic influenza vaccine (H5N1 strain NIBRG-14) | Phase 2 | Pandemic Influenza |
| 100U EV71 vaccine with adjuvant | Phase 2 | Infection, Viral, Enterovirus |
| sIPV-bOPV-bOPV vaccination schedule | Phase 3 | Poliomyelitis |
| split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14) | Phase 2 | Influenza |
| Quadrivalent influenza vaccine(0.5ml) | Phase 3 | Seasonal Influenza |
| Influenza Vaccine (Split Virion), Inactivated, Quadrivalent | Phase 3 | Seasonal Influenza |
| Experimental vaccine | Phase 3 | Poliomyelitis |
| Quadrivalent influenza vaccine(0.25ml) | Phase 3 | Seasonal Influenza |
| bivalent enterovirus vaccine (Vero cell), inactivated | Phase 3 | Hand, Foot, and Mouth Disease（HFMD) |
Price & technical context
3-month
+0.0%
6-month
+0.0%
12-month
+0.0%
52-wk range
$6.47–$6.47
vs 50-day MA
-0.0%
vs 200-day MA
-0.0%
Realized vol
0.0%
Max drawdown
0.0%
Daily closes through 2026-08-26. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SVA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.